Human Papillomavirus Vaccine Market Report 2024 (Global Edition)

Global Human Papillomavirus Vaccine Market Report 2024 Market Size Split by Type (Tetravalent, Nonavalent, Bivalent), by Disease Indication (Cervical Cancer, Anal Cancer, Vulvar & Vaginal Cancer, Peni...

Human Papillomavirus Vaccine Market Report Description

We have various report editions of Human Papillomavirus Vaccine Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Human Papillomavirus Vaccine Market Insights Video

Competitive Landscape of the Human Papillomavirus Vaccine Market

In the Human Papillomavirus Vaccine market's competitive landscape. In order to enhance the efficacy of the human papillomavirus vaccine in adults, major actors are emphasizing product launches and investments in research and development. In order to capitalize on lucrative revenue opportunities, these organizations are adhering to the most recent developments in the human papillomavirus vaccine market.

In March 2023, Roche Diagnostics and the Cancer Awareness Prevention and Early Detection Trust (CAPED) have executed a Memorandum of Understanding (MoU). CAPED is a non-profit organization that advocates for the early detection, prevention, and awareness of cancer. In an effort to establish a cervical cancer screening program in India, the partnership was established. (Source: https://diagnostics.roche.com/in/en_gb/news-listing/2023/caped-and-roche-diagnostics-india-launch-cervical-cancer-screening-programme.html) In June 2020, MSD, GSK, Innovax, Serum Institute of India Pvt. Ltd. (SII), and Walvax, vaccine manufacturers, increased the availability of human papillomavirus (HPV) vaccines for Gavi-supported countries on the eve of the Global Vaccine Summit 2020. These countries have one of the highest cervical cancer burdens in the world. (Source: https://www.unicef.org/press-releases/hpv-vaccine-manufacturers-commit-provide-enough-supply-immunize-least-84-million) In January 2020, The Food and Drug Administration has increased the recommended age for receiving the human papillomavirus (HPV) vaccine to 45. (Source: https://www.fda.gov/news-events/press-announcements/fda-approves-expanded-use-gardasil-9-include-individuals-27-through-45-years-old#:~:text=The%20U.S.%20Food%20and%20Drug,aged%2027%20through%2045%20years.)

Top Companies Market Share in Human Papillomavirus Vaccine Industry: (In no particular order of Rank)

• GlaxoSmithKline Plc
• Johnson & Johnson
• Merck & Co.
• Inc.
• AstraZeneca Plc
• Sanofi S.A.
• Novartis AG
• Serum Institute of India Pvt. Ltd.
• Bharat Biotech
• Inovio Pharmaceuticals
• Inc
• Xenetic Biosciences
• Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Human Papillomavirus Vaccine Market

Which Region Dominates the Human Papillomavirus Vaccine Market in 2024?

According to Cognitive Market Research, North America currently dominates the Human Papillomavirus Vaccines market, and the region is expected to have significant growth during the projected period. The increasing frequency of HPV-related diseases such cervical, anal, and oropharyngeal cancers has increased need for efficient immunization programs. Market growth also depends on government support and financing for HPV vaccine efforts, including public awareness and national immunization programs.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). Due to government vaccination policy changes, HPV vaccine demand increased in the area. Asia Pacific market growth is driven by increased vaccination demand and HPV illness prevalence.

The current report Scope analyzes Human Papillomavirus Vaccine Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Human Papillomavirus Vaccine Market

According to Cognitive Market Research, the global Human Papillomavirus Vaccine market size was estimated at USD 4325.2 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 1730.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.4% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Human Papillomavirus Vaccine market with a market size of USD 1365.03 million in 2024 and is anticipated to grow at a CAGR of 11.2% during the projected period. The U.S. market's strong governmental support for vaccination programs and a high prevalence of HPV-related malignancies.
• The Canada Human Papillomavirus Vaccine market had a market share of USD 207.61 million in 2024 and is anticipated to grow at a CAGR of 12.2% during the projected period. Canada’s rising high vaccination coverage rates and comprehensive public health initiatives.
• The Mexico Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 11.9% during the projected period, with a market size of USD 157.44 million in 2024.

Europe Human Papillomavirus Vaccine Market

According to Cognitive Market Research, the global Human Papillomavirus Vaccine market size was estimated at USD 4325.2 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 1297.56 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.7% from 2024 to 2031.

• The United Kingdom Human Papillomavirus Vaccine market had a market share of USD 217.99 million in 2024 and is anticipated to grow at a CAGR of 12.5% during the projected period. In the UK, Human Papillomavirus Vaccine sales see an upswing due to the increasing school-based vaccination initiatives that are comprehensive.
• The France Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 10.9% during the projected period, with a market size of USD 119.38 million in 2024.
• According to Cognitive Market Research, the German Human Papillomavirus Vaccine market size was valued at USD 256.92 million in 2024 and is anticipated to grow at a CAGR of 11.9% during the projected period. In Germany, Human Papillomavirus Vaccine surged due to the comprehensive insurance coverage and expensive healthcare expenditures.
• The Italy Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 11.1% during the projected period, with a market size of USD 111.59 million in 2024.
• The Russia Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 10.7% during the projected period, with a market size of USD 201.12 million in 2024.
• The Spain Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 10.8% during the projected period with a market size of USD 106.40 million in 2024
• The Luxembourg Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 11.8% during the projected period, with a market size of USD 40.22 million in 2024.
• The Portugal Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 11.5% during the projected period, with a market size of USD 27.25 million in 2024.
• The Greece Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 12.0% during the projected period, with a market size of USD 15.57 million in 2024.
• The Rest of Europe's Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 10.4% during the projected period, with a market size of USD 201.12 million in 2024.

Asia Pacific Human Papillomavirus Vaccine Market

According to Cognitive Market Research, the global Human Papillomavirus Vaccine market size was estimated at USD 4325.2 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 994.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.2% from 2024 to 2031.

• According to Cognitive Market Research, the China Human Papillomavirus Vaccine market size was valued at USD 447.66 million in 2024 and is anticipated to grow at a CAGR of 14.7% during the projected period. Human Papillomavirus Vaccine surged in China due to increasing number of steps taken by the government to include HPV vaccinations into national immunization programs.
• The Japan Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 13.7% during the projected period, with a market size of USD 137.28 million in 2024.
• The India Human Papillomavirus Vaccine market had a market share of USD 119.38 million in 2024 and is anticipated to grow at a CAGR of 17.0% during the projected period. India's increasing collaborations between the public and commercial sectors to improve vaccination accessibility.
• The South Korean Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 14.3% during the projected period, with a market size of USD 99.48 million in 2024.
• The Australian Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 14.9% during the projected period, with a market size of USD 51.73 million in 2024.
• The South East Asia Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 16.2% during the projected period, with a market size of USD 68.64 million in 2024.
• The Rest of Asia Pacific Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 15.0% during the projected period, with a market size of USD 70.63 million in 2024.

South America Human Papillomavirus Vaccine Market

According to Cognitive Market Research, the global Human Papillomavirus Vaccine market size was estimated at USD 4325.2 Million, out of which the Latin America held the market share of around 5% of the global revenue with a market size of USD 216.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Human Papillomavirus Vaccine market size was valued at USD 92.56 million in 2024 and is anticipated to grow at a CAGR of 13.2% during the projected period. Human Papillomavirus Vaccines flourished in Brazil due to increasing government funding for vaccination initiatives.
• Argentina's Human Papillomavirus Vaccine market had a market share of USD 36.33 million in 2024 and is anticipated to grow at a CAGR of 13.5% during the projected period. Argentina's increasing public awareness and education campaigns regarding HPV prevention.
• Colombia Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 12.4% during the projected period, with a market size of USD 19.25 million in 2024.
• Peru Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 12.8% during the projected period, with a market size of USD 17.73 million in 2024.
• Chile Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 12.9% during the projected period, with a market size of USD 15.57 million in 2024.
• The Rest of Latin America's Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 11.7% during the projected period, with a market size of USD 34.82 million in 2024.

Middle East and Africa Human Papillomavirus Vaccine Market

According to Cognitive Market Research, the global Human Papillomavirus Vaccine market size was estimated at USD 4325.2 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 86.50 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.9% from 2024 to 2031..

• The GCC Countries Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 13.7% during the projected period, with a market size of USD 37.02 million in 2024. Human Papillomavirus Vaccine sales flourish due to the increase in government initiatives and healthcare investments to combat HPV-related maladies.
• The Egypt Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 13.2% during the projected period, with a market size of USD 9.08 million in 2024.
• The South Africa Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 13.9% during the projected period, with a market size of USD 13.67 million in 2024. Human Papillomavirus Vaccine sales flourished in South Africa due to increasing awareness and education campaigns regarding HPV vaccination.
• The Turkey Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 12.4% during the projected period, with a market size of USD 7.44 million in 2024.
• The Nigeria Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 12.0% during the projected period, with a market size of USD 9.08 million in 2024.
• The Rest of the MEA Human Papillomavirus Vaccine market is anticipated to see growth at a CAGR of 11.9% during the projected period, with a market size of USD 10.21 million in 2024.

Human Papillomavirus Vaccine Market Analysis

Human Papillomavirus Vaccine Market Type Segment Analysis

According to Cognitive Market Research, Tetravalent Human Papillomavirus Vaccines are likely to dominate the Human Papillomavirus Vaccine Market over the forecast period, because it protects against many HPV strains. It protects against HPV types 6, 11, 16, and 18, which cause most HPV-related illnesses. Types 6 and 11 cause 90% of genital warts and types 16 and 18 70% of cervical malignancies. Tetravalent vaccines are efficient and popular because to their broad coverage, which helps them dominate the market. Additionally, its effectiveness and safety profile support its wider use.

The Nonavalent is the fastest-growing segment in the Human Papillomavirus Vaccine Market. The nonavalent vaccine's broad coverage prevents HPV-related illnesses, increasing uptake and demand. Regional approval and inclusion in national vaccination programs also boost its market expansion.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Human Papillomavirus Vaccine Industry. Request a Free Sample PDF!

Human Papillomavirus Vaccine Market Disease Indication Segment Analysis

According to Cognitive Market Research, the Cervical Cancer segment holds the largest share of the market. Over 80% of cervical cancer cases are detected in developing nations. These reasons should enhance the global human papillomavirus vaccine market throughout the projected period.

In the Human Papillomavirus Vaccine Market, the Oropharyngeal Cancer sector has been expanding at a rapid pace. Increased HPV-related oropharyngeal malignancies, especially in males, drive this growth. Awareness of the association between HPV and oropharyngeal malignancies and the wider protective coverage of nonavalent vaccinations contribute to the fast growth of this sector.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Human Papillomavirus Vaccine Industry Vertical Segment Analysis

Human Papillomavirus Vaccine Market Industry Vertical Segment Analysis

According to Cognitive Market Research, The Public and Private Alliances segment holds the largest market share, because governments, non-profits, and private firms collaborate to promote vaccination access and coverage. Gavi, the Vaccine Alliance, funds and supports HPV immunization initiatives in low- and middle-income countries.

In the Human Papillomavirus Vaccine market, the rapidly growing sector is the Government Entities category. Global government immunization campaigns for HPV-related infections are driving this rise. Governments are establishing policies and supporting projects to increase vaccination availability, especially in low- and middle-income nations.

• Public and Private Alliances
• Government Entities
• Physicians
• Others

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion